Alzamend Neuro, Inc.
ALZN
$1.47
$0.010.69%
NASDAQ
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 165.17% | 11.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.63% | 120.19% | |||
| Operating Income | -30.63% | -120.19% | |||
| Income Before Tax | -30.51% | -119.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.51% | -119.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.51% | -119.72% | |||
| EBIT | -30.63% | -120.19% | |||
| EBITDA | -31.02% | -123.62% | |||
| EPS Basic | -24.69% | -95.27% | |||
| Normalized Basic EPS | -24.70% | -95.24% | |||
| EPS Diluted | -24.69% | -95.27% | |||
| Normalized Diluted EPS | -24.70% | -95.24% | |||
| Average Basic Shares Outstanding | 4.67% | 12.53% | |||
| Average Diluted Shares Outstanding | 4.67% | 12.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||